Figure 1

Fig. 1

## Scheme 1. Modification of SBL mutants with Chiral Auxiliaries.

$$R = S \xrightarrow{QR^{1}} (R)-a R^{1} = Me$$

$$(R)-b R^{1} = H$$

$$(R)-b R^{1} = H$$

$$(R)-b R^{1} = H$$

$$(R)-a R^{1} = Me$$

$$(R)-a R^{1} = R^{1} = R^{1}$$

$$(R)-a R^{1} = R^{1} = R^{1}$$

$$(R)-a R^{1} = R^{1}$$

$$R = S$$
 $(R)-g R^1 = Ph$ 
 $(R)-h R^1 = Bn$ 
 $(R)-i$ 

The corresponding (S) MTS ligands follow the same code scheme (i.e. (S)-a, (S)-b, (S)-d, (S)-e, (S)-f, (S)-g, (S)-h, (S)-i).

Fig. 2

## Scheme 2. Synthesis of Mandelate-based Ligands

OR OR OR OR (iv) OR 
$$R^1$$
 (vii) SSO<sub>2</sub>CH<sub>3</sub>

(i) (R)-2 R = H, R<sup>1</sup> = H (ii) (V) (R)-6 R = Me, R<sup>1</sup> = OH (Viii) (R)-12 R = MOM (R)-12 R = MOM (R)-7 R = MOM, R<sup>1</sup> = OH (Viii) (R)-1b R = H

(iii) (R)-4 R = H, R<sup>1</sup> = Me (Vi) (R)-8 R = Me, R<sup>1</sup> = OSO<sub>2</sub>CH<sub>3</sub> (V) (R)-9 R = MOM, R<sup>1</sup> = OSO<sub>2</sub>CH<sub>3</sub> (V) (R)-9 R = MOM, R<sup>1</sup> = OSO<sub>2</sub>CH<sub>3</sub> (V) (R)-10 R = Me, R<sup>1</sup> = Br (R)-11 R = MOM, R<sup>1</sup> = Br

Reagents: (i)  $Me_2SO_4$ , NaOH,  $H_2O$ , 37%; (ii) MeOH,  $H^{\dagger}$ ; (ii) MOM-CI,  $CH_2CI_2$ ,  $Et_3N$  (90% 2 steps); (iv) For (R)-3:  $BH_3$ , THF, 82%; For (R)-5:  $LiBH_4$ , THF, 97%; (v)  $MeSO_2CI$ ,  $CH_2CI_2$ ,  $Et_3N$ ; For (R)-8: 100%; (vi) LiBr, acetone; For (R)-10: 84%; For (R)-11: 78% 2 steps; (vii)  $NaSSO_2CH_3$ , DMF; For (R)-12: 61%; (viii) TFA,  $H_2O$ , 82%.

<del>a talaine, talais les proposes de la populaçõe de proposes de proposes de la populaçõe de la propose de la propose de la populaçõe de la popu</del>

## Scheme 3. Synthesis of Oxazolidinone-based Ligands

Reagents: (i) KOH, DMSO, Br  $(CH_2)_nBr$ ; (ii) NaSSo<sub>2</sub>CH<sub>3</sub>, DMF.

## Scheme 4. Synthesis of Indanol-based Ligands

$$H_2N$$
  $OH$   $(i)$   $HN$   $O$   $(R)$ -24

(iii) (R)-25 R = Br (R)-1i R = SSO<sub>2</sub>CH<sub>3</sub>

Reagents: (i) triphosgene, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 100%; (ii) KOH, DMSO, Br(CH<sub>2</sub>)<sub>3</sub>Br; (iii) NaSSO<sub>2</sub>CH<sub>3</sub>, DMF.

Fig. 5





Fig. 6A






Fig. 6C




Fig. 7A




Fig. 7B

Fig. 8